Evidence map›Paper›PMID 42098408›Full record

ArticleLeukemia2026

CAR T-cells targeting CD117 effectively eliminate mast cells in preclinical models of advanced systemic mastocytosis.

Anne Kaiser, Veronika Lysenko, Renier Myburgh, Laura Volta, Christian Pellegrino, Alexandre P A Theocharides, Deborah Christen, Jens Panse, Marco M Bühler, Michel Arock and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anne KaiserDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Veronika LysenkoDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-6886-5444
Renier MyburghDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Laura VoltaDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Christian PellegrinoDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-7898-9988
Alexandre P A TheocharidesDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-1535-8692
Deborah ChristenDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Uniklinik Aachen, RWTH Aachen University, Aachen, Germany.
Jens PanseDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Uniklinik Aachen, RWTH Aachen University, Aachen, Germany.ORCID http://orcid.org/0000-0001-6316-3112
Marco M BühlerComprehensive Cancer Center Zurich (CCCZ), Zurich, Switzerland.ORCID http://orcid.org/0000-0003-0850-3326
Michel ArockCEREMAST, Department of Hematological Biology, Pitié-Salpêtrière Hospital, Paris Sorbonne University, Paris, France.ORCID http://orcid.org/0000-0002-3990-4408
Joseph ButterfieldDivisions of Allergy, Asthma and Immunology, Mayo Clinic, Rochester, Minnesota, USA.
Marcelo A S de ToledoDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Uniklinik Aachen, RWTH Aachen University, Aachen, Germany.ORCID http://orcid.org/0000-0003-4318-7381
Peter ValentDepartment of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-0456-5095
Martin ZenkeDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Uniklinik Aachen, RWTH Aachen University, Aachen, Germany.ORCID http://orcid.org/0000-0002-1107-3251
Tim H BrümmendorfDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, Uniklinik Aachen, RWTH Aachen University, Aachen, Germany.
Markus G ManzDepartment of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. markus.manz@usz.ch.ORCID http://orcid.org/0000-0002-4676-7931

Funding

Alexander von Humboldt-Stiftung (Alexander von Humboldt Foundation) 99999.001703/2014-05Deutsche Forschungsgemeinschaft (German Research Foundation) DFG ZE432/10-1Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030_184747/1
6 · The paper itself

Abstract

Systemic mastocytosis (SM) is characterized by uncontrolled expansion of neoplastic mast cells (MCs) and their accumulation in various tissues and organs, ranging from indolent variants to more advanced forms (advSM). Although several MC- and SM-expressed cell surface antigens have been identified, no immune therapy has been developed for advSM so far. The receptor tyrosine kinase KIT (CD117) is highly expressed on MCs, exceeding the levels of expression on hematopoietic stem and progenitor cells (HSPC). Therefore, targeting CD117 in advSM could be of therapeutic value. In this study, we assessed the therapeutic potential of anti-CD117 chimeric antigen receptor (CAR) T-cells to target neoplastic MCs in SM. In vitro, anti-CD117-CAR T-cells efficiently lysed several SM-related human MC cell lines, MCs differentiated from SM patient-derived induced pluripotent stem (iPS) cells, and neoplastic bone marrow cells obtained from SM patients. Furthermore, in immunocompromised mice engrafted with an advSM-like MC cell line, repetitive applications of anti-CD117-CAR T-cells were able to inhibit MC expansion. These data may pave the way for the development of anti-CD117-CAR T-cell therapies in advSM.

Indexed as

Immunotherapy, AdoptiveMast CellsMastocytosis, SystemicProto-Oncogene Proteins c-kitReceptors, Chimeric AntigenT-LymphocytesAnimalsDisease Models, AnimalHumansMiceKIT protein, humanProto-Oncogene Proteins c-kitReceptors, Chimeric Antigen

Identifiers

PMID42098408
PMCPMC13323065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.